Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technol
PAVmed Partners With Cancer Center to Advance Care
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage m
Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $26 From $30
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)
PAVmed Non-GAAP EPS of -$1.33 Beats by $0.47, Revenue of $1.05M Beats by $0.02M
PAVmed 4Q Loss/Shr $1.98 >PAVM
PAVmed 4Q Loss/Shr $1.98 >PAVM
Press Release: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire NEW YORK, March 26, 2024 Lucid's quarterly revenue increased 33 percent sequentially Launched wh
PAVmed Q4 2024 Earnings Preview
Preview: PAVmed's Earnings
PAVmed (NASDAQ:PAVM) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement.Analysts estimate that PAVmed will report an
Lucid Diagnostics Announces Positive Data From the First Prospective Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population
PAVmed Launches Incubator to Advance Existing Pipeline Technologies Including PortIO, EsoCure and CarpX
The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with PortIO NEW YORK, March 21, 2024 /PRNewswi
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical...
No Data